Skip to main content

Table 2 Pharmacokinetic analysis of ACY-1215

From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment

  ACY-1215 plasma concentration ACY-1215 Brain concentration Brain to plasma ration
Dose (mg/kg) Dose route Sampling
time (hr)
Mean (ng/mL) SD CV (%) Mean (ng/g) SD CV (%) Mean SD CV (%)
30 Oral Predose BQL N/A N/A NA NA NA BQL NA NA
0.5 1226.67 63.51 5.18 15.20 3.65 24.01 0.01 0.00 27.61
1 561.00 128.36 22.88 5.61 NA NA NA NA NA
4 60.60 26.63 43.94 BQL NA NA NA NA NA
8 18.02 9.78 54.29 BQL NA NA NA NA NA
  1. Abbreviations: BQL below the quantifiable limit of 1.00 ng/mL of ACY-1215 in mouse plasma and brain homogenates, CV coefficient of variation, NA not available, SD standard deviation